Insight on Pharmaceuticals and Healthcare in United Kingdom

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

5EU: Pricing, Reimbursement and Regulatory Update

Datamonitor’s report 5EU: Pricing, Reimbursement, and Regulatory Update provides an overview of developments regarding healthcare reforms, drug regulation, and drug pricing and reimbursement in France, Germany, Italy, Spain, and the UK.

Published By Datamonitor
28 Oct 2011 $1520
Buy
Report
Report

Biosimilars: Regulatory Update

Datamonitor’s report Biosimilars: Regulatory Update provides analysis on key developments in biosimilar regulations globally. It includes an overview of the background behind these events and popular strategic responses.

Published By Datamonitor
08 Dec 2011 $1520
Buy
Report
Report

Biosimilars: Regulatory Update

Datamonitor’s report Biosimilars: Regulatory Update provides analysis on key developments in biosimilar regulations globally.

Published By Datamonitor
09 Aug 2011 $1520
Buy
Report
Report

Branded Prescription Pharmaceutical Sales Outlook to 2016

An analysis of global sales forecasts for the Branded PharmaVitae Universe during 2011–16.

Published By Datamonitor
03 Feb 2012 $2800
Buy
Brief
Brief

Brief: Hepatitis C/AASLD 2010

This brief is an overview of the HCV highlights from the 2010 American Association of the Study of Liver Disease meeting. It discusses pivotal data for telaprevir and boceprevir, results for TMC435 and data from interferon-sparing studies.

Published By Datamonitor
13 Dec 2010 $400
Buy
Report
Report

Case Study: Autism Spectrum Disorders – Public awareness and physician detailing will drive market growth

This report examines the opportunities and threats within the autism spectrum disorders (ASDs) market. The analysis is intended to support company strategy and decision-making by providing actionable recommendations in the current treatment pathway.

Published By Datamonitor
16 Apr 2012 $1520
Buy
Report
Report

Case Study: HIV - Better differential pricing strategies are needed to ensure access to HIV drugs

This module discusses differential pricing for antiretrovirals as a strategy that enhances access to drugs while preserving incentives for pharmaceutical companies.

Published By Datamonitor
18 May 2011 $1520
Buy
Report
Report

Case Study: Personalized Cancer Therapy - Anticipated competition threatens to dampen commercial potential of new approvals

Overview of targeted cancer therapies and biomarkers, with in-depth analysis of drug and companion diagnostic development, commercial potential, role of regulatory authorities in the seven major markets and key pipeline personalized cancer therapies.

Published By Datamonitor
16 Jul 2012 $1520
Buy
Report
Report

Case Study: Sepsis - Xigris’ disappointing performance creates a market opportunity for improved sepsis therapies

The Surviving Sepsis Campaign has created an increased focus on reducing levels of mortality from sepsis. Eli Lilly/BioCritica’s Xigris has been unable to capitalize on what remains a potentially lucrative therapy area with significant unmet needs.

Published By Datamonitor
17 May 2011 $1520
Buy
Report
Report

Commercial Insight: Disease Modification in Rheumatoid Arthritis – Market awaits game changing therapies and strategies

Coverage of disease-modifying drugs in the seven major rheumatoid arthritis markets, including indication-specific 10-year forecasts (using both sales and patient-based approaches), detailed brand profiling and an in-depth patient-based case study.

Published By Datamonitor
15 Dec 2010 $6400
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.